The global market for Hepatitis B Antiviral Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

North American market for Hepatitis B Antiviral Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Hepatitis B Antiviral Drugs is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Hepatitis B Antiviral Drugs in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Hepatitis B Antiviral Drugs include GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Hepatitis B Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Antiviral Drugs.

The Hepatitis B Antiviral Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hepatitis B Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hepatitis B Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hepatitis B Antiviral Drugs Market Report

Report Metric	Details
Report Name	Hepatitis B Antiviral Drugs Market
Segment by Type	Nucleos(t)ide Analogues Interferons
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, Qilu pharmaceutical, Fujian Cosunter Pharma, Xiamen Amoytop Biotech, YaoPharma, Kelun Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis B Antiviral Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Hepatitis B Antiviral Drugs Market report?

Ans: The main players in the Hepatitis B Antiviral Drugs Market are GSK, Bristol Myers Squibb, Gilead Sciences, Novartis, Roche, Merck, Johnson & Johnson, Dawnrays Pharmaceutical, Hansoh Pharmaceutical, Chia Tai-Tianqing Pharmaceutical, Qilu pharmaceutical, Fujian Cosunter Pharma, Xiamen Amoytop Biotech, YaoPharma, Kelun Pharmaceutical

What are the Application segmentation covered in the Hepatitis B Antiviral Drugs Market report?

Ans: The Applications covered in the Hepatitis B Antiviral Drugs Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Hepatitis B Antiviral Drugs Market report?

Ans: The Types covered in the Hepatitis B Antiviral Drugs Market report are Nucleos(t)ide Analogues, Interferons

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hepatitis B Antiviral Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Nucleos(t)ide Analogues

1.2.3 Interferons

1.3 Market by Application

1.3.1 Global Hepatitis B Antiviral Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hepatitis B Antiviral Drugs Market Perspective (2020-2031)

2.2 Global Hepatitis B Antiviral Drugs Growth Trends by Region

2.2.1 Global Hepatitis B Antiviral Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hepatitis B Antiviral Drugs Historic Market Size by Region (2020-2025)

2.2.3 Hepatitis B Antiviral Drugs Forecasted Market Size by Region (2026-2031)

2.3 Hepatitis B Antiviral Drugs Market Dynamics

2.3.1 Hepatitis B Antiviral Drugs Industry Trends

2.3.2 Hepatitis B Antiviral Drugs Market Drivers

2.3.3 Hepatitis B Antiviral Drugs Market Challenges

2.3.4 Hepatitis B Antiviral Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hepatitis B Antiviral Drugs Players by Revenue

3.1.1 Global Top Hepatitis B Antiviral Drugs Players by Revenue (2020-2025)

3.1.2 Global Hepatitis B Antiviral Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Hepatitis B Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hepatitis B Antiviral Drugs Revenue

3.4 Global Hepatitis B Antiviral Drugs Market Concentration Ratio

3.4.1 Global Hepatitis B Antiviral Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hepatitis B Antiviral Drugs Revenue in 2024

3.5 Global Key Players of Hepatitis B Antiviral Drugs Head office and Area Served

3.6 Global Key Players of Hepatitis B Antiviral Drugs, Product and Application

3.7 Global Key Players of Hepatitis B Antiviral Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hepatitis B Antiviral Drugs Breakdown Data by Type

4.1 Global Hepatitis B Antiviral Drugs Historic Market Size by Type (2020-2025)

4.2 Global Hepatitis B Antiviral Drugs Forecasted Market Size by Type (2026-2031)

5 Hepatitis B Antiviral Drugs Breakdown Data by Application

5.1 Global Hepatitis B Antiviral Drugs Historic Market Size by Application (2020-2025)

5.2 Global Hepatitis B Antiviral Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Hepatitis B Antiviral Drugs Market Size (2020-2031)

6.2 North America Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hepatitis B Antiviral Drugs Market Size by Country (2020-2025)

6.4 North America Hepatitis B Antiviral Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hepatitis B Antiviral Drugs Market Size (2020-2031)

7.2 Europe Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hepatitis B Antiviral Drugs Market Size by Country (2020-2025)

7.4 Europe Hepatitis B Antiviral Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hepatitis B Antiviral Drugs Market Size (2020-2031)

8.2 Asia-Pacific Hepatitis B Antiviral Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hepatitis B Antiviral Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Hepatitis B Antiviral Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hepatitis B Antiviral Drugs Market Size (2020-2031)

9.2 Latin America Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hepatitis B Antiviral Drugs Market Size by Country (2020-2025)

9.4 Latin America Hepatitis B Antiviral Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hepatitis B Antiviral Drugs Market Size (2020-2031)

10.2 Middle East & Africa Hepatitis B Antiviral Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hepatitis B Antiviral Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Hepatitis B Antiviral Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GSK

11.1.1 GSK Company Details

11.1.2 GSK Business Overview

11.1.3 GSK Hepatitis B Antiviral Drugs Introduction

11.1.4 GSK Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.1.5 GSK Recent Development

11.2 Bristol Myers Squibb

11.2.1 Bristol Myers Squibb Company Details

11.2.2 Bristol Myers Squibb Business Overview

11.2.3 Bristol Myers Squibb Hepatitis B Antiviral Drugs Introduction

11.2.4 Bristol Myers Squibb Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.2.5 Bristol Myers Squibb Recent Development

11.3 Gilead Sciences

11.3.1 Gilead Sciences Company Details

11.3.2 Gilead Sciences Business Overview

11.3.3 Gilead Sciences Hepatitis B Antiviral Drugs Introduction

11.3.4 Gilead Sciences Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.3.5 Gilead Sciences Recent Development

11.4 Novartis

11.4.1 Novartis Company Details

11.4.2 Novartis Business Overview

11.4.3 Novartis Hepatitis B Antiviral Drugs Introduction

11.4.4 Novartis Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.4.5 Novartis Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Hepatitis B Antiviral Drugs Introduction

11.5.4 Roche Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.5.5 Roche Recent Development

11.6 Merck

11.6.1 Merck Company Details

11.6.2 Merck Business Overview

11.6.3 Merck Hepatitis B Antiviral Drugs Introduction

11.6.4 Merck Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.6.5 Merck Recent Development

11.7 Johnson & Johnson

11.7.1 Johnson & Johnson Company Details

11.7.2 Johnson & Johnson Business Overview

11.7.3 Johnson & Johnson Hepatitis B Antiviral Drugs Introduction

11.7.4 Johnson & Johnson Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.7.5 Johnson & Johnson Recent Development

11.8 Dawnrays Pharmaceutical

11.8.1 Dawnrays Pharmaceutical Company Details

11.8.2 Dawnrays Pharmaceutical Business Overview

11.8.3 Dawnrays Pharmaceutical Hepatitis B Antiviral Drugs Introduction

11.8.4 Dawnrays Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.8.5 Dawnrays Pharmaceutical Recent Development

11.9 Hansoh Pharmaceutical

11.9.1 Hansoh Pharmaceutical Company Details

11.9.2 Hansoh Pharmaceutical Business Overview

11.9.3 Hansoh Pharmaceutical Hepatitis B Antiviral Drugs Introduction

11.9.4 Hansoh Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.9.5 Hansoh Pharmaceutical Recent Development

11.10 Chia Tai-Tianqing Pharmaceutical

11.10.1 Chia Tai-Tianqing Pharmaceutical Company Details

11.10.2 Chia Tai-Tianqing Pharmaceutical Business Overview

11.10.3 Chia Tai-Tianqing Pharmaceutical Hepatitis B Antiviral Drugs Introduction

11.10.4 Chia Tai-Tianqing Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.10.5 Chia Tai-Tianqing Pharmaceutical Recent Development

11.11 Qilu pharmaceutical

11.11.1 Qilu pharmaceutical Company Details

11.11.2 Qilu pharmaceutical Business Overview

11.11.3 Qilu pharmaceutical Hepatitis B Antiviral Drugs Introduction

11.11.4 Qilu pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.11.5 Qilu pharmaceutical Recent Development

11.12 Fujian Cosunter Pharma

11.12.1 Fujian Cosunter Pharma Company Details

11.12.2 Fujian Cosunter Pharma Business Overview

11.12.3 Fujian Cosunter Pharma Hepatitis B Antiviral Drugs Introduction

11.12.4 Fujian Cosunter Pharma Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.12.5 Fujian Cosunter Pharma Recent Development

11.13 Xiamen Amoytop Biotech

11.13.1 Xiamen Amoytop Biotech Company Details

11.13.2 Xiamen Amoytop Biotech Business Overview

11.13.3 Xiamen Amoytop Biotech Hepatitis B Antiviral Drugs Introduction

11.13.4 Xiamen Amoytop Biotech Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.13.5 Xiamen Amoytop Biotech Recent Development

11.14 YaoPharma

11.14.1 YaoPharma Company Details

11.14.2 YaoPharma Business Overview

11.14.3 YaoPharma Hepatitis B Antiviral Drugs Introduction

11.14.4 YaoPharma Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.14.5 YaoPharma Recent Development

11.15 Kelun Pharmaceutical

11.15.1 Kelun Pharmaceutical Company Details

11.15.2 Kelun Pharmaceutical Business Overview

11.15.3 Kelun Pharmaceutical Hepatitis B Antiviral Drugs Introduction

11.15.4 Kelun Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025)

11.15.5 Kelun Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Dawnrays Pharmaceutical

Hansoh Pharmaceutical

Chia Tai-Tianqing Pharmaceutical

Qilu Pharmaceutical

Fujian Cosunter Pharma

Xiamen Amoytop Biotech

YaoPharma

Kelun Pharmaceutical

List of Tables

Table 1. Global Hepatitis B Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Nucleos(t)ide Analogues

Table 3. Key Players of Interferons

Table 4. Global Hepatitis B Antiviral Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Hepatitis B Antiviral Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Hepatitis B Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Hepatitis B Antiviral Drugs Market Share by Region (2020-2025)

Table 8. Global Hepatitis B Antiviral Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Hepatitis B Antiviral Drugs Market Share by Region (2026-2031)

Table 10. Hepatitis B Antiviral Drugs Market Trends

Table 11. Hepatitis B Antiviral Drugs Market Drivers

Table 12. Hepatitis B Antiviral Drugs Market Challenges

Table 13. Hepatitis B Antiviral Drugs Market Restraints

Table 14. Global Hepatitis B Antiviral Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Hepatitis B Antiviral Drugs Market Share by Players (2020-2025)

Table 16. Global Top Hepatitis B Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Antiviral Drugs as of 2024)

Table 17. Ranking of Global Top Hepatitis B Antiviral Drugs Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Hepatitis B Antiviral Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Hepatitis B Antiviral Drugs, Headquarters and Area Served

Table 20. Global Key Players of Hepatitis B Antiviral Drugs, Product and Application

Table 21. Global Key Players of Hepatitis B Antiviral Drugs, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Hepatitis B Antiviral Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Hepatitis B Antiviral Drugs Revenue Market Share by Type (2020-2025)

Table 25. Global Hepatitis B Antiviral Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Hepatitis B Antiviral Drugs Revenue Market Share by Type (2026-2031)

Table 27. Global Hepatitis B Antiviral Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Hepatitis B Antiviral Drugs Revenue Market Share by Application (2020-2025)

Table 29. Global Hepatitis B Antiviral Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Hepatitis B Antiviral Drugs Revenue Market Share by Application (2026-2031)

Table 31. North America Hepatitis B Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Hepatitis B Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Hepatitis B Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Hepatitis B Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Hepatitis B Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Hepatitis B Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Hepatitis B Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Hepatitis B Antiviral Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Hepatitis B Antiviral Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Hepatitis B Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Hepatitis B Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Hepatitis B Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Hepatitis B Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Hepatitis B Antiviral Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Hepatitis B Antiviral Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 46. GSK Company Details

Table 47. GSK Business Overview

Table 48. GSK Hepatitis B Antiviral Drugs Product

Table 49. GSK Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 50. GSK Recent Development

Table 51. Bristol Myers Squibb Company Details

Table 52. Bristol Myers Squibb Business Overview

Table 53. Bristol Myers Squibb Hepatitis B Antiviral Drugs Product

Table 54. Bristol Myers Squibb Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 55. Bristol Myers Squibb Recent Development

Table 56. Gilead Sciences Company Details

Table 57. Gilead Sciences Business Overview

Table 58. Gilead Sciences Hepatitis B Antiviral Drugs Product

Table 59. Gilead Sciences Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 60. Gilead Sciences Recent Development

Table 61. Novartis Company Details

Table 62. Novartis Business Overview

Table 63. Novartis Hepatitis B Antiviral Drugs Product

Table 64. Novartis Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 65. Novartis Recent Development

Table 66. Roche Company Details

Table 67. Roche Business Overview

Table 68. Roche Hepatitis B Antiviral Drugs Product

Table 69. Roche Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 70. Roche Recent Development

Table 71. Merck Company Details

Table 72. Merck Business Overview

Table 73. Merck Hepatitis B Antiviral Drugs Product

Table 74. Merck Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 75. Merck Recent Development

Table 76. Johnson & Johnson Company Details

Table 77. Johnson & Johnson Business Overview

Table 78. Johnson & Johnson Hepatitis B Antiviral Drugs Product

Table 79. Johnson & Johnson Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 80. Johnson & Johnson Recent Development

Table 81. Dawnrays Pharmaceutical Company Details

Table 82. Dawnrays Pharmaceutical Business Overview

Table 83. Dawnrays Pharmaceutical Hepatitis B Antiviral Drugs Product

Table 84. Dawnrays Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 85. Dawnrays Pharmaceutical Recent Development

Table 86. Hansoh Pharmaceutical Company Details

Table 87. Hansoh Pharmaceutical Business Overview

Table 88. Hansoh Pharmaceutical Hepatitis B Antiviral Drugs Product

Table 89. Hansoh Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 90. Hansoh Pharmaceutical Recent Development

Table 91. Chia Tai-Tianqing Pharmaceutical Company Details

Table 92. Chia Tai-Tianqing Pharmaceutical Business Overview

Table 93. Chia Tai-Tianqing Pharmaceutical Hepatitis B Antiviral Drugs Product

Table 94. Chia Tai-Tianqing Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 95. Chia Tai-Tianqing Pharmaceutical Recent Development

Table 96. Qilu pharmaceutical Company Details

Table 97. Qilu pharmaceutical Business Overview

Table 98. Qilu pharmaceutical Hepatitis B Antiviral Drugs Product

Table 99. Qilu pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 100. Qilu pharmaceutical Recent Development

Table 101. Fujian Cosunter Pharma Company Details

Table 102. Fujian Cosunter Pharma Business Overview

Table 103. Fujian Cosunter Pharma Hepatitis B Antiviral Drugs Product

Table 104. Fujian Cosunter Pharma Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 105. Fujian Cosunter Pharma Recent Development

Table 106. Xiamen Amoytop Biotech Company Details

Table 107. Xiamen Amoytop Biotech Business Overview

Table 108. Xiamen Amoytop Biotech Hepatitis B Antiviral Drugs Product

Table 109. Xiamen Amoytop Biotech Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 110. Xiamen Amoytop Biotech Recent Development

Table 111. YaoPharma Company Details

Table 112. YaoPharma Business Overview

Table 113. YaoPharma Hepatitis B Antiviral Drugs Product

Table 114. YaoPharma Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 115. YaoPharma Recent Development

Table 116. Kelun Pharmaceutical Company Details

Table 117. Kelun Pharmaceutical Business Overview

Table 118. Kelun Pharmaceutical Hepatitis B Antiviral Drugs Product

Table 119. Kelun Pharmaceutical Revenue in Hepatitis B Antiviral Drugs Business (2020-2025) & (US$ Million)

Table 120. Kelun Pharmaceutical Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Hepatitis B Antiviral Drugs Picture

Figure 2. Global Hepatitis B Antiviral Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hepatitis B Antiviral Drugs Market Share by Type: 2024 VS 2031

Figure 4. Nucleos(t)ide Analogues Features

Figure 5. Interferons Features

Figure 6. Global Hepatitis B Antiviral Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Hepatitis B Antiviral Drugs Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Others Case Studies

Figure 11. Hepatitis B Antiviral Drugs Report Years Considered

Figure 12. Global Hepatitis B Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Hepatitis B Antiviral Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Hepatitis B Antiviral Drugs Market Share by Region: 2024 VS 2031

Figure 15. Global Hepatitis B Antiviral Drugs Market Share by Players in 2024

Figure 16. Global Top Hepatitis B Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Antiviral Drugs as of 2024)

Figure 17. The Top 10 and 5 Players Market Share by Hepatitis B Antiviral Drugs Revenue in 2024

Figure 18. North America Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Hepatitis B Antiviral Drugs Market Share by Country (2020-2031)

Figure 20. United States Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Hepatitis B Antiviral Drugs Market Share by Country (2020-2031)

Figure 24. Germany Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Hepatitis B Antiviral Drugs Market Share by Region (2020-2031)

Figure 32. China Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Hepatitis B Antiviral Drugs Market Share by Country (2020-2031)

Figure 40. Mexico Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Hepatitis B Antiviral Drugs Market Share by Country (2020-2031)

Figure 44. Turkey Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Hepatitis B Antiviral Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. GSK Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 48. Bristol Myers Squibb Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 49. Gilead Sciences Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 50. Novartis Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 51. Roche Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 52. Merck Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 53. Johnson & Johnson Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 54. Dawnrays Pharmaceutical Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 55. Hansoh Pharmaceutical Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 56. Chia Tai-Tianqing Pharmaceutical Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 57. Qilu pharmaceutical Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 58. Fujian Cosunter Pharma Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 59. Xiamen Amoytop Biotech Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 60. YaoPharma Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 61. Kelun Pharmaceutical Revenue Growth Rate in Hepatitis B Antiviral Drugs Business (2020-2025)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions